KalVista Pharmaceuticals (KALV) Free Cash Flow Growth (3y) (2019 - 2025)
KalVista Pharmaceuticals (KALV) Free Cash Flow Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -32.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -32.30% |
| Apr 30, 2025 | -14.68% |
| Oct 31, 2024 | -25.89% |
| Jul 31, 2024 | -30.75% |
| Apr 30, 2024 | -10.27% |
| Jan 31, 2024 | -54.18% |
| Oct 31, 2023 | -35.53% |
| Jul 31, 2023 | -94.92% |
| Apr 30, 2023 | -21.61% |
| Jan 31, 2023 | 10.80% |
| Oct 31, 2022 | -37.89% |
| Jul 31, 2022 | -27.66% |
| Apr 30, 2022 | -35.57% |
| Jan 31, 2022 | -9.47% |
| Oct 31, 2021 | -30.25% |
| Jul 31, 2021 | -38.54% |
| Apr 30, 2021 | -16.32% |
| Jan 31, 2021 | -31.44% |
| Oct 31, 2020 | -2.90% |
| Jul 31, 2020 | 7.48% |